Home Cart 0 Sign in  

[ CAS No. 36805-97-7 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 36805-97-7
Chemical Structure| 36805-97-7
Structure of 36805-97-7 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 36805-97-7 ]

Related Doc. of [ 36805-97-7 ]

Alternatived Products of [ 36805-97-7 ]
Product Citations

Product Citations

Artem Chayka ; Michal Česnek ; Erika Kužmová , et al. DOI: PubMed ID:

Abstract: Yohimbine, a natural alkaloid and a nonselective adrenoceptor antagonist, possesses potential benefits in treating inflammatory disorders and sepsis. Nevertheless, its broader clinical use faces challenges due to its low receptor selectivity. A structure–activity relationship study of novel yohimbine analogues identified amino of yohimbic acid as potent and selective ADRA2A antagonists. Specifically, amino 4n, in comparison to yohimbine, showed a 6-fold higher ADRA1A/ADRA2A selectivity index (SI > 556 for 4n) and a 25-fold higher ADRA2B/ADRA2A selectivity index. Compound 4n also demonstrated high plasma and microsomal stability, moderate-to-low membrane permeability determining its limited ability to cross the blood–brain barrier, and negligible toxicity on nontumor normal human dermal fibroblasts. Compound 4n represents an important complementary pharmacological tool to study the involvement of adrenoceptor subtypes in pathophysiologic conditions such as inflammation and sepsis and a novel candidate for further preclinical development to treat ADRA2A-mediated pathologies.

Purchased from AmBeed: ; ;

Product Details of [ 36805-97-7 ]

CAS No. :36805-97-7 MDL No. :MFCD00015002
Formula : C11H25NO2 Boiling Point : -
Linear Structure Formula :(C4H9O)2CHN(CH3)2 InChI Key :DBNQIOANXZVWIP-UHFFFAOYSA-N
M.W : 203.32 Pubchem ID :547712
Synonyms :

Safety of [ 36805-97-7 ]

Signal Word:Danger Class:3
Precautionary Statements:P501-P240-P210-P233-P243-P241-P242-P264-P280-P370+P378-P337+P313-P305+P351+P338-P362+P364-P303+P361+P353-P332+P313-P403+P235 UN#:1993
Hazard Statements:H225-H315-H319 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 36805-97-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 36805-97-7 ]

[ 36805-97-7 ] Synthesis Path-Downstream   1~7

  • 1
  • [ 403-45-2 ]
  • [ 36805-97-7 ]
  • [ 676560-01-3 ]
  • 2
  • [ 32501-05-6 ]
  • [ 36805-97-7 ]
  • [ 295327-36-5 ]
YieldReaction ConditionsOperation in experiment
In DMF (N,N-dimethyl-formamide); at 20℃; for 1h; This monomer was generated in situ (during library synthesis) from 4-aza-oxindole and dimethylformamide di-t-butylacetal in DMF.Monomer 9 and Monomer 10 were generated in situ by preparing stock solutions of the corresponding aza-oxindole. For example, 20.1 mg of 4-aza-oxindole was dissolved in 4.0 mL of ethanol. Both of the precursors for monomers 9 and 10 were transferred (0.20 ml/well) to a 96-well dry heating block (vwrBRAND Dry Block Heater, cat No.13259-066) according to the map below where M represents the monomer and A represents the amine. The ethanol was evaporated off at 50 C. until it was clear that there was no solvent remaining. DMF (0.20 mL) was added followed by the addition of dimethylformamide di-t-butylacetal (0.003 mL) and this remained at room temperature for 1 h.
  • 3
  • [ 5654-97-7 ]
  • [ 36805-97-7 ]
  • [ 295327-35-4 ]
YieldReaction ConditionsOperation in experiment
In N,N-dimethyl-formamide; Monomer 9: 3-Dimethylaminomethylene-<strong>[5654-97-7]7-azaoxindole</strong> This monomer was generated in situ (during library synthesis) from <strong>[5654-97-7]7-azaoxindole</strong> and dimethylformamide di-t-butylacetal in DMF.
In DMF (N,N-dimethyl-formamide); at 20℃; for 1h; This monomer was generated in situ (during library synthesis) from 7-aza-oxindole and dimethylformamide di-t-butylacetal in DMF.Monomer 9 and Monomer 10 were generated in situ by preparing stock solutions of the corresponding aza-oxindole. For example, 20.1 mg of 4-aza-oxindole was dissolved in 4.0 mL of ethanol. Both of the precursors for monomers 9 and 10 were transferred (0.20 ml/well) to a 96-well dry heating block (vwrBRAND Dry Block Heater, cat No.13259-066) according to the map below where M represents the monomer and A represents the amine. The ethanol was evaporated off at 50 C. until it was clear that there was no solvent remaining. DMF (0.20 mL) was added followed by the addition of dimethylformamide di-t-butylacetal (0.003 mL) and this remained at room temperature for 1 h.
  • 4
  • [ 1798-06-7 ]
  • [ 36805-97-7 ]
  • [ 856250-87-8 ]
YieldReaction ConditionsOperation in experiment
44% In toluene; at 80℃; for 2h; A solution of 4-iodo phenyl acetic acid (Lancaster, 1. 31g, 5mmmmol) in anhydrous toluene (10mL) was heated to 80C and treated with a solution of N, N- dimethyl fonnamide di-t-butyl acetal. After 2 h the reaction mixture was cooled to ambient temperature and subjected to flash column chromatography on silica gel (23-400 mesh) using 10% ethyl acetate in hexane as the eluent to afford the title compound (0.7g, 44%). 1H NMR (300 MHz, CDCl3) : 8 7.62 (d, 2H, J= 8.2Hz), 7.01 (d, 2H, J= 8.2Hz), 3. 45 (s, 2H), 1.43 (s, 9H).
44% In toluene; at 80℃; for 2h; 4-Iodo-tert-butyl phenvl acetate (Reagent 10); A solution of 4-iodo phenyl acetic acid (Lancaster, 1. 31g, 5mmmol) in anhydrous toluene (lOmL) was heated to 80C and treated with a solution of N, N- dimethyl formamide di-t-butyl acetal. After 2 h the reaction mixture was cooled to ambient temperature and subjected to flash column chromatography on silica gel (23-400 mesh) using 10% ethyl acetate in hexane as the eluent to afford the title compound (0.7g, 44%). IH NMR (300 MHz, CDCl3) : 8 7.62 (d, 2H, J= 8. 2Hz), 7.01 (d, 2H, J= 8. 2Hz), 3.45 (s, 2H), 1.43 (s, 9H).
  • 5
  • [ 32501-05-6 ]
  • [ 36805-97-7 ]
  • 3-[(dimethylamino)methylidene]-1H-pyrrolo[3,2-b]pyridin-2-one [ No CAS ]
YieldReaction ConditionsOperation in experiment
In N,N-dimethyl-formamide; 3-[(Dimethylamino)methylidene]-1H-pyrrolo[3,2-b]pyridin-2-one This monomer was generated in situ (during library synthesis) from <strong>[32501-05-6]1,3-dihydro-2H-pyrrolo[3,2-b]pyridin-2-one</strong> and dimethylformamide di-t-butylacetal in DMF.
  • 6
  • [ 5654-97-7 ]
  • [ 63-74-1 ]
  • [ 36805-97-7 ]
  • [ 295327-24-1 ]
YieldReaction ConditionsOperation in experiment
36 mg (21%) With methanesulfonic acid; sodium hydrogencarbonate; In methanol; ethanol; water; N,N-dimethyl-formamide; Example 3A 4-[(2-Oxo-1,2-dihydro-3H-pyrrolo[2,3-b]pyridin-3-ylidene)methyl]amino}benzenesulfonamide Dimethylformamide di-tert-butyl acetal (180 mg, 0.89 mmol) was added to a solution of 1,2-dihydro-3H-pyrrolo[2,3-b]pyridin-2-one (70 mg, 0.52 mmol) in 0.25 ml DMF, and the reaction mixture was slowly warmed to 100 C. The cooled solution was then diluted with 5 ml of ethanol. Sulfanilamide (172 mg, 1.00 mmol) and methanesulfonic acid (60 mg, 0.63 mmol) were added, and the reaction mixture was stirred at reflux for 2 hours. The cooled solution was diluted with 4 ml of water, treated with NaHCO3 (70 mg, 0.83 mmol) and stirred 10 min. The resulting solid was filtered, washed with water and ethanol, and then suspended in boiling methanol and filtered upon cooling. Inorganics were removed by filtration through a short silica gel column, eluding with DMF. The resulting solution was diluted with an equal volume of ice water, and the suspension was refrigerated overnight. The solid was isolated by filtration and dried to give 36 mg (21%) of the title compound as a yellow solid: 1H NMR (400 MHz, DMSO-d6) (4:1 ratio of Z:E isomers): delta (Z) 11.07 (s, 1H), 10.76 (d, J=12.4 Hz, 1H), 8.67 (d, J=12.5 Hz, 1H), 7.92 (d, J=5.1 Hz, 1H), 7.84 (d, J=7.3 Hz,
36 mg (21%) With methanesulfonic acid; sodium hydrogencarbonate; In methanol; ethanol; water; N,N-dimethyl-formamide; EXAMPLE 3 4-[(2-oxo-1,2-Dihydro-3H-pyrrolo[2,3-b]pyridin-3-ylidene)methyl]amino}benzenesulfonamide Dimethylformamide di-tert-butyl acetal (180 mg, 0.89 mmol) was added to a solution of 1,2-dihydro-3H-pyrrolo[2,3-b]pyridin-2-one (70 mg, 0.52 mmol) in 0.25 ml DMF, and the reaction mixture was slowly warmed to 100 C. The cooled solution was then diluted with 5 ml of ethanol. Sulfanilamide (172 mg, 1.00 mmol) and methanesulfonic acid (60 mg, 0.63 mmol) were added, and the reaction mixture was stirred at reflux for 2 h. The cooled solution was diluted with 4 ml of water, treated with NaHCO3 (70 mg, 0.83 mmol) and stirred 10 min. The resulting solid was filtered, washed with water and ethanol, and then suspended in boiling methanol and filtered upon cooling. Inorganics were removed by filtration through a short silica gel column, eluding with DMF. The resulting solution was diluted with an equal volume of ice water, and the suspension was refrigerated overnight. The solid was isolated by filtration and dried to give 36 mg (21%) of the title compound as a yellow solid: 1H NMR (400 MHz, DMSO-d6) (4:1 ratio of Z:E isomers): delta (Z) 11.07 (s, 1H), 10.76 (d, J=12.4 Hz, 1H), 8.67 (d, J=12.5 Hz, 1H), 7.92 (d, J=5.1 Hz, 1H), 7.84 (d, J=7.3 Hz, 1H), 7.77 (d, J=8.7 Hz, 2H), 7.55 (d, J=8.6 Hz, 2H), 7.25 (s, 2H), 6.93 (dd, J=7.3, 5.1 Hz, 1H); (E) 10.79 (s, 1H), 9.70 (d, J=13.4 Hz, 1H), 8.23 (d, J=7.3 Hz, 1H). ESI-MS m/z 315 (M-H). Anal. Calcd. for C14H12N4O3S. 0.5 H2O: C, 51.68; H, 4.03; N, 17.03. Found: C, 51.75; H, 3.95; N, 17.26.
  • 7
  • [ 5654-97-7 ]
  • [ 36805-97-7 ]
  • 3-dimethylaminomethylene-1,3-dihydropyrrolo[2,3-b]pyridin-2-one [ No CAS ]
YieldReaction ConditionsOperation in experiment
In N,N-dimethyl-formamide; 3-[(Dimethylamino)methylidene]-1H-pyrrolo[2,3-b]pyridin-2-one This compound was prepared in situ (during library synthesis) from <strong>[5654-97-7]1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one</strong> and dimethylformamide di-t-butylacetal in DMF.
Recommend Products
Same Skeleton Products

Technical Information

Historical Records

Related Functional Groups of
[ 36805-97-7 ]

Aliphatic Chain Hydrocarbons

Chemical Structure| 5815-08-7

[ 5815-08-7 ]

tert-Butoxy bis(dimethylamino)methane

Similarity: 0.61

Chemical Structure| 16066-84-5

[ 16066-84-5 ]

tert-Butyl methylcarbamate

Similarity: 0.53

Ethers

Chemical Structure| 5815-08-7

[ 5815-08-7 ]

tert-Butoxy bis(dimethylamino)methane

Similarity: 0.61

Amines

Chemical Structure| 5815-08-7

[ 5815-08-7 ]

tert-Butoxy bis(dimethylamino)methane

Similarity: 0.61

Chemical Structure| 16066-84-5

[ 16066-84-5 ]

tert-Butyl methylcarbamate

Similarity: 0.53

; ;